As seen in Fig. 5A, knockdown or pharmacological inhibition of DOT1L could block TGF-β1-induced upregulation in the protein levels of lung fibrosis markers, such as CTGF, FN, and MMP9. Here, CCN2 is linked to pulmonary fibrosis.